Bliss GVS Pharma Gears Up for Q3 Reveal on 10th February; Check Key Expectations Here
- February 9, 2026
- Posted by: Ekta Dhawan
- Category: News
Click and Sign Up to Get Live Updates on Q3 Results
Bliss GVS Pharma’s Q3 results FY26 are scheduled to be announced on 10th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Bliss GVS Pharma Q3 Results 2026 Preview
- Bliss GVS Pharma’s revenue is expected to be in the range of ₹210.42 crore, a 3.34% YoY decrease.
- Profit After Tax, or PAT, is projected to rise 3% YoY.
- Net profit is ₹23.80 crore, a rise 3% YoY
- EBITDA to fall 35.53%
Bliss GVS Pharma Share Performance
- Over the past six months, Bliss GVS Pharma’s share price has risen by 15.61% to ₹200.00.
- Moreover, over the past year, the stock has increased by 34.52%.
- Despite this weak short-term performance, Bliss GVS Pharma’s stock has delivered a financially sound 10.97% return over the past 5 years.
- As of 9th February 2026, the stock traded at ₹200.75 per share.
About Bliss GVS Pharma
Bliss GVS Pharma Limited is an Indian pharmaceutical company headquartered in Mumbai, Maharashtra, engaged in the development, manufacturing, marketing, and export of pharmaceutical formulations for both domestic and global markets. Bliss GVS Pharma increased revenue by ₹846 crore, operating income by ₹97.76 crore, and net income by ₹90.26 crore. During the same period, total assets increased by ₹1,300.84 crore
Key Factors to Watch for Bliss GVS Pharma Q3 Results FY26
- Revenue Growth: Trend in domestic and export sales across key therapeutic segments.
- Operating Margins: Stability or improvement in margins amid raw material and compliance costs.
- Profit Quality: Share of core operating profit versus other income in overall earnings.
- Export Performance: Growth in overseas markets and regulatory approvals for new geographies.
- Cost Control: Management of manufacturing, employee, and logistics expenses.
- Working Capital & Cash Flow: Movement in receivables, inventory, and operating cash flows.
Final Thoughts
Bliss GVS Pharma will announce its Q3 FY26 results on 10th February 2026. Analysts expect 3.34% revenue growth, a 3% rises in PAT, and a 35.53% fall in EBITDA. Bliss GVS Pharma’ sales bookings recovery, timely project deliveries, and margin stability are supported by strong customer collections.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Alfred Herbert India Ltd Q3 Results FY26 Preview: PAT falls 3%
Salora International Q3 Results FY26 Preview: PAT falls 18.54%
Kuantum Papers Q3 Results FY26 Preview: PAT falls 29.85%
AK Capital Services Ltd Q3 Results FY26 Preview: PAT falls 16.86%
